Skip to main content
. Author manuscript; available in PMC: 2013 Aug 5.
Published in final edited form as: Vaccine. 2011 Dec 4;30(5):922–930. doi: 10.1016/j.vaccine.2011.11.089

Fig. 1.

Fig. 1

Locations of modifications on HIV-1 gp120 to focus CD4bs antibody responses: Structure of the JR-FL gp120 core (PDB ID 2B4C) denoting the locations of glycan attachment sites (naturally occurring (yellow) and those inserted for hyperglycosylation (orange)) and engineered Ala substitutions (light blue). The location of residues that upon alanine substitution result in ≥50% reduction in b12 binding to gp120 (ref. [28]) are shown in green. The location of Gly-Asp-Met-Arg (GDMR) residues at the center of the CD4bs that are necessary for binding of several non-NAbs, but not b12 (ref. [28]), is also marked (dark khaki).